A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Gastroesophageal Reflux Disease
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Crossover AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 19 years and 50 years
- Gender
- Both males and females
Description
This study is to compare the safety, pharmacokinetic characteristics and pharmacodynamics characteristics of AD-214 10/600mg compared with administration of Rabeprazole 10mg in healthy volunteers.
This study is to compare the safety, pharmacokinetic characteristics and pharmacodynamics characteristics of AD-214 10/600mg compared with administration of Rabeprazole 10mg in healthy volunteers.
Tracking Information
- NCT #
- NCT04494243
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Seunghwan Lee, M.D.,Ph.D Seoul National University Hospital
Get Well Soon